Ok, we may not exactly be at the point where we’re determining employment by genetic status, but CRISPR still gives some ethicists pause when it comes to human applications. However, a team of researchers led by Shoukhrat Mitalipov—whose greatest hits include creating “three-parent” monkeys and a technique for creating stem cells out of skin cells—decided they weren’t gonna let China have all the fun with pushing ethical boundaries. The team’s work culminated in the first gene-editing of a human embryo performed on US soil. They also did it better than their Chinese counterparts have been able to so far, with fewer unintended errors in portions of the DNA that weren’t being actively operated on.
Do you ever get tired at your job? You know, those days when the work just keeps piling up until you end up sending an email talking about the “Key Onion Leader” you want at your conference next year? Well turns out, basal stem cells can mess up at their jobs too… except their mess-ups can lead to the second-most prevalent form of lung cancer instead of confusion over vegetable management. The correlation was identified by University of Melbourne researchers who realized there was high basal stem cell growth in smokers since those cells help replace cells lost from smoking. The discovery gives innovator companies a drug target to stop lung cancer’s progress in its tracks.
Bayer plans to unlock some of the potential within its ranks by establishing start-up-like entities. Bayer is trying the spin-out approach to developing next-gen solutions in human, animal, and agriculture technologies such as stem cells, RNA inhibition/activation, the microbiome, and DNA editing. One of the first, and probably best-funded is Casebia, a joint venture founded by Bayer and CRISPR Therapeutics. Casebia was initially funded with $300M from Bayer and another $35M was spent to give Bayer an unspecified stake in CRISPR. Casebia has access to gene-editing technology from CRISPR in specific disease areas, as well as access to protein engineering expertise and relevant disease know-how through Bayer. Prescription for success? Not sure, but take two of these and call me in the morning.
Great news for individuals suffering from rheumatoid arthritis and not so great news for pharma companies holding patents on the monoclonal antibody-based biologics currently used to treat RA. An Australian biotech, Mesoblast, completed Phase II clinical trials on its stem cell treatment for rheumatoid arthritis to astounding results (some have inserted the word “cure” here). In a test designed to identify whether the stem cell treatment is efficient—by achieving 20% relief of signs and symptoms—researchers instead saw a 70% improvement among more than one-third of the patients who received MPC-300-IV. Since some RA patients are unable to take biologics, a stem cell therapy could benefit wider audiences.
People smarter than most have developed a new kind of bio-ink. No, you can’t get it at Staples. But don’t let that stop you from getting excited about this stem cell-containing ink that can be used to engineer bone and cartilage via 3D printing. The team developed a formulation that contains two different polymer based components—one extracted from seaweed, the other a synthetic polymer used in the medical industry—and a retrofitted benchtop 3D printer to generate a full-size tracheal cartilage ring in just 5 weeks. Sounds slow for the person who could really use a tracheal cartilage ring right about now. Potential uses include joints for hip and knee replacement surgeries as well as nose reconstruction. Lord Voldemort would be pleased.